EMA Application withdrawn: Lacosamide Pain UCB Pharma (lacosamide) — UCB Pharma S.A.

View source ↗

Summary

EC withdrawal of lacosamide pain application from UCB Pharma for diabetic neuropathies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy

Drugs mentioned

• Lacosamide (Lacosamide)

Snippet

Status: Application withdrawn. Therapeutic area: Diabetic Neuropathies. MAH: UCB Pharma S.A.. Decision date: 31/12/2009